Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Nguyen

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal for Immunotherapy of Cancer|August 24, 2022
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatmentsSylvain Nguyen, Mathieu F Chevalier, Sulayman Benmerzoug, et al.
European Urology Open Science|November 26, 2021
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer PatientsSulayman Benmerzoug, Mathieu F Chevalier, Laura Villier, et al.
European Urology Focus|June 20, 2021
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer PatientsSulayman Benmerzoug, Mathieu F Chevalier, Maëlle Verardo, et al.
European Journal of Immunology|July 24, 2020
Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T-cell responses to acute and chronic viral infectionPatricia Aparicio-Domingo, Hélène Cannelle, Matthew B Buechler, et al.
European Urology Open Science|October 10, 2022
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety ProfileIlaria Lucca, Laurent Derré, Valérie Cesson, et al.
Frontiers in Immunology|November 28, 2025
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patientsWalther Brochier, Sylvain Nguyen, Valérie Cesson, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, et al.
Cancers|June 28, 2023
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate CancerRitaparna Ahmed, Leyder Elena Lozano, Amandine Anastasio, et al.
Nature|April 16, 2025
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiationAmir Hosseini, Abhinav Dhall, Nemo Ikonen, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal for Immunotherapy of Cancer|August 24, 2022
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatmentsSylvain Nguyen, Mathieu F Chevalier, Sulayman Benmerzoug, et al.
European Urology Open Science|November 26, 2021
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer PatientsSulayman Benmerzoug, Mathieu F Chevalier, Laura Villier, et al.
European Urology Focus|June 20, 2021
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer PatientsSulayman Benmerzoug, Mathieu F Chevalier, Maëlle Verardo, et al.
European Journal of Immunology|July 24, 2020
Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T-cell responses to acute and chronic viral infectionPatricia Aparicio-Domingo, Hélène Cannelle, Matthew B Buechler, et al.
European Urology Open Science|October 10, 2022
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety ProfileIlaria Lucca, Laurent Derré, Valérie Cesson, et al.
Frontiers in Immunology|November 28, 2025
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patientsWalther Brochier, Sylvain Nguyen, Valérie Cesson, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, et al.
Cancers|June 28, 2023
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate CancerRitaparna Ahmed, Leyder Elena Lozano, Amandine Anastasio, et al.
Nature|April 16, 2025
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiationAmir Hosseini, Abhinav Dhall, Nemo Ikonen, et al.
Pageof 3